Please enable JavaScript to continue using this application.

Compare $ADMA vs $BEAM | Chartloom

Compare

$ADMA vs $BEAM

ADMA Biologics Inc · Beam Therapeutics Inc

ADMA

ADMA Biologics Inc

BEAM

Beam Therapeutics Inc

Compare $ADMA vs $BEAM

Comparing ADMA Biologics Inc and Beam Therapeutics Inc

ADMAADMA Biologics Inc

BEAMBeam Therapeutics Inc

ADMAADMA Biologics Inc

Market cap

$2.40B

P/E (TTM)

14.12x

Forward P/E (NTM)

12.78x

Forward P/S (NTM)

4.05x

Rev growth (TTM)

8.0%

YTD performance

-42.1%

52W performance

-29.1%

FCF yield

4.8%

BEAMBeam Therapeutics Inc

Market cap

$2.64B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

38.86x

Rev growth (TTM)

158.9%

YTD performance

-5.3%

52W performance

-4.8%

FCF yield

-14.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ADMA

BEAM

Detailed metrics comparison

ADMA

ADMA Biologics Inc

BEAM

Beam Therapeutics Inc

Market Cap

ADMA$2.40B

BEAM$2.64B

Enterprise Value

ADMA$2.46B

BEAM$2.52B

Price

ADMA$10.36

BEAM$25.70

P/E Ratio

ADMA14.12x

BEAMN/A

P/S Ratio

ADMA4.69x

BEAM16.95x

EV/Sales

ADMA4.81x

BEAM16.18x

EV/EBITDA

ADMA11.39x

BEAM0.00x

P/B Ratio

ADMA5.33x

BEAM2.37x

P/FCF Ratio

ADMA20.66x

BEAMN/A

EV/FCF

ADMA21.18x

BEAM-6.77x

PEG Ratio

ADMAN/A

BEAMN/A

Forward P/E (NTM)

ADMA12.78x

BEAMN/A

Forward P/S (NTM)

ADMA4.05x

BEAM38.86x

Revenue (TTM)

ADMA$512M

BEAM$156M

Revenue Growth (YoY)

ADMA8.0%

BEAM158.9%

Forward Rev Growth

ADMA17.6%

BEAM17.9%

Gross Margin (TTM)

ADMA64.7%

BEAM0.0%

Operating Margin (TTM)

ADMA43.4%

BEAM0.0%

EBITDA Margin (TTM)

ADMA42.2%

BEAM-228.0%

Net Margin (TTM)

ADMA33.0%

BEAM-54.7%

FCF Margin (TTM)

ADMA22.7%

BEAM-238.9%

Net Income (TTM)

ADMA$169M

BEAM$-85M

FCF (TTM)

ADMA$116M

BEAM$-373M

EPS (TTM)

ADMA$0.73

BEAM-$0.82

ROE (TTM)

ADMA39.6%

BEAM-770.0%

ROA (TTM)

ADMA26.6%

BEAM-604.0%

ROIC (TTM)

ADMA30.1%

BEAM-737.0%

Cash

ADMA$136M

BEAM$220M

Debt

ADMA$197M

BEAM$100M

Net Cash/Debt

ADMA$-61M

BEAM$120M

Current Ratio (TTM)

ADMA6.97x

BEAM14.57x

Quick Ratio (TTM)

ADMA3.62x

BEAM14.25x

Debt/Equity (TTM)

ADMA0.48x

BEAM0.09x

Debt/Assets (TTM)

ADMA0.0%

BEAM0.0%

Interest Coverage (TTM)

ADMAN/A

BEAMN/A

Net Debt/EBITDA (TTM)

ADMA0.00x

BEAM0.00x

Beta

ADMA0.70

BEAM2.26

52W Performance

ADMA-29.1%

BEAM-4.8%

YTD Performance

ADMA-42.1%

BEAM-5.3%

% from 52W High

ADMA-49.4%

BEAM-32.8%

% from 52W Low

ADMA43.7%

BEAM27.0%

Asset Turnover (TTM)

ADMA0.81x

BEAM0.11x

FCF Yield (TTM)

ADMA4.8%

BEAM-14.1%

Earnings Yield (TTM)

ADMA7.0%

BEAM-3.2%

Dividend Yield (TTM)

ADMAN/A

BEAMN/A

Rule of 40

ADMA30.7

BEAM-80.0

EV/GP/RG

ADMA0.47

BEAMN/A

Ticker research

View ADMA research View BEAM research

Metric	ADMA ADMA Biologics Inc	BEAM Beam Therapeutics Inc
Market & Valuation
Market Cap	$2.40B	$2.64B
Enterprise Value	$2.46B	$2.52B
Price	$10.36	$25.70
P/E Ratio	14.12x	N/A
P/S Ratio	4.69x	16.95x
EV/Sales	4.81x	16.18x
EV/EBITDA	11.39x	0.00x
P/B Ratio	5.33x	2.37x
P/FCF Ratio	20.66x	N/A
EV/FCF	21.18x	-6.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	12.78x	N/A
Forward P/S (NTM)	4.05x	38.86x
Revenue & Growth
Revenue (TTM)	$512M	$156M
Revenue Growth (YoY)	8.0%	158.9%
Forward Rev Growth	17.6%	17.9%
Profitability
Gross Margin (TTM)	64.7%	0.0%
Operating Margin (TTM)	43.4%	0.0%
EBITDA Margin (TTM)	42.2%	-228.0%
Net Margin (TTM)	33.0%	-54.7%
FCF Margin (TTM)	22.7%	-238.9%
Net Income (TTM)	$169M	$-85M
FCF (TTM)	$116M	$-373M
EPS (TTM)	$0.73	-$0.82
ROE (TTM)	39.6%	-770.0%
ROA (TTM)	26.6%	-604.0%
ROIC (TTM)	30.1%	-737.0%
Financial Health
Cash	$136M	$220M
Debt	$197M	$100M
Net Cash/Debt	$-61M	$120M
Current Ratio (TTM)	6.97x	14.57x
Quick Ratio (TTM)	3.62x	14.25x
Debt/Equity (TTM)	0.48x	0.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.70	2.26
52W Performance	-29.1%	-4.8%
YTD Performance	-42.1%	-5.3%
% from 52W High	-49.4%	-32.8%
% from 52W Low	43.7%	27.0%
Efficiency & Yields
Asset Turnover (TTM)	0.81x	0.11x
FCF Yield (TTM)	4.8%	-14.1%
Earnings Yield (TTM)	7.0%	-3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	30.7	-80.0
EV/GP/RG	0.47	N/A
Ticker research	View ADMA research	View BEAM research

Valuation

P/E Ratio

ADMA

14.12x

P/S Ratio

ADMA

4.69x

BEAM

16.95x

EV/FCF

BEAM

-6.77x

ADMA

21.18x

Growth & revenue

Revenue Growth TTM

BEAM

158.9%

ADMA

8.0%

Forward Revenue Growth

BEAM

17.9%

ADMA

17.6%

Profitability & performance

Gross Margin

ADMA

64.7%

BEAM

0.0%

ROE

ADMA

39.6%

BEAM

-770.0%

FCF Yield %

ADMA

4.8%

BEAM

-14.1%

52-Week Performance

BEAM

-4.8%

ADMA

-29.1%

Detailed metrics comparison

ADMA

ADMA Biologics Inc

BEAM

Beam Therapeutics Inc

Market Cap

ADMA$2.40B

BEAM$2.64B

Enterprise Value

ADMA$2.46B

BEAM$2.52B

Price

ADMA$10.36

BEAM$25.70

P/E Ratio

ADMA14.12x

BEAMN/A

P/S Ratio

ADMA4.69x

BEAM16.95x

EV/Sales

ADMA4.81x

BEAM16.18x

EV/EBITDA

ADMA11.39x

BEAM0.00x

P/B Ratio

ADMA5.33x

BEAM2.37x

P/FCF Ratio

ADMA20.66x

BEAMN/A

EV/FCF

ADMA21.18x

BEAM-6.77x

PEG Ratio

ADMAN/A

BEAMN/A

Forward P/E (NTM)

ADMA12.78x

BEAMN/A

Forward P/S (NTM)

ADMA4.05x

BEAM38.86x

Revenue (TTM)

ADMA$512M

BEAM$156M

Revenue Growth (YoY)

ADMA8.0%

BEAM158.9%

Forward Rev Growth

ADMA17.6%

BEAM17.9%

Gross Margin (TTM)

ADMA64.7%

BEAM0.0%

Operating Margin (TTM)

ADMA43.4%

BEAM0.0%

EBITDA Margin (TTM)

ADMA42.2%

BEAM-228.0%

Net Margin (TTM)

ADMA33.0%

BEAM-54.7%

FCF Margin (TTM)

ADMA22.7%

BEAM-238.9%

Net Income (TTM)

ADMA$169M

BEAM$-85M

FCF (TTM)

ADMA$116M

BEAM$-373M

EPS (TTM)

ADMA$0.73

BEAM-$0.82

ROE (TTM)

ADMA39.6%

BEAM-770.0%

ROA (TTM)

ADMA26.6%

BEAM-604.0%

ROIC (TTM)

ADMA30.1%

BEAM-737.0%

Cash

ADMA$136M

BEAM$220M

Debt

ADMA$197M

BEAM$100M

Net Cash/Debt

ADMA$-61M

BEAM$120M

Current Ratio (TTM)

ADMA6.97x

BEAM14.57x

Quick Ratio (TTM)

ADMA3.62x

BEAM14.25x

Debt/Equity (TTM)

ADMA0.48x

BEAM0.09x

Debt/Assets (TTM)

ADMA0.0%

BEAM0.0%

Interest Coverage (TTM)

ADMAN/A

BEAMN/A

Net Debt/EBITDA (TTM)

ADMA0.00x

BEAM0.00x

Beta

ADMA0.70

BEAM2.26

52W Performance

ADMA-29.1%

BEAM-4.8%

YTD Performance

ADMA-42.1%

BEAM-5.3%

% from 52W High

ADMA-49.4%

BEAM-32.8%

% from 52W Low

ADMA43.7%

BEAM27.0%

Asset Turnover (TTM)

ADMA0.81x

BEAM0.11x

FCF Yield (TTM)

ADMA4.8%

BEAM-14.1%

Earnings Yield (TTM)

ADMA7.0%

BEAM-3.2%

Dividend Yield (TTM)

ADMAN/A

BEAMN/A

Rule of 40

ADMA30.7

BEAM-80.0

EV/GP/RG

ADMA0.47

BEAMN/A

Ticker research

View ADMA research View BEAM research

Metric	ADMA ADMA Biologics Inc	BEAM Beam Therapeutics Inc
Market & Valuation
Market Cap	$2.40B	$2.64B
Enterprise Value	$2.46B	$2.52B
Price	$10.36	$25.70
P/E Ratio	14.12x	N/A
P/S Ratio	4.69x	16.95x
EV/Sales	4.81x	16.18x
EV/EBITDA	11.39x	0.00x
P/B Ratio	5.33x	2.37x
P/FCF Ratio	20.66x	N/A
EV/FCF	21.18x	-6.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	12.78x	N/A
Forward P/S (NTM)	4.05x	38.86x
Revenue & Growth
Revenue (TTM)	$512M	$156M
Revenue Growth (YoY)	8.0%	158.9%
Forward Rev Growth	17.6%	17.9%
Profitability
Gross Margin (TTM)	64.7%	0.0%
Operating Margin (TTM)	43.4%	0.0%
EBITDA Margin (TTM)	42.2%	-228.0%
Net Margin (TTM)	33.0%	-54.7%
FCF Margin (TTM)	22.7%	-238.9%
Net Income (TTM)	$169M	$-85M
FCF (TTM)	$116M	$-373M
EPS (TTM)	$0.73	-$0.82
ROE (TTM)	39.6%	-770.0%
ROA (TTM)	26.6%	-604.0%
ROIC (TTM)	30.1%	-737.0%
Financial Health
Cash	$136M	$220M
Debt	$197M	$100M
Net Cash/Debt	$-61M	$120M
Current Ratio (TTM)	6.97x	14.57x
Quick Ratio (TTM)	3.62x	14.25x
Debt/Equity (TTM)	0.48x	0.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.70	2.26
52W Performance	-29.1%	-4.8%
YTD Performance	-42.1%	-5.3%
% from 52W High	-49.4%	-32.8%
% from 52W Low	43.7%	27.0%
Efficiency & Yields
Asset Turnover (TTM)	0.81x	0.11x
FCF Yield (TTM)	4.8%	-14.1%
Earnings Yield (TTM)	7.0%	-3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	30.7	-80.0
EV/GP/RG	0.47	N/A
Ticker research	View ADMA research	View BEAM research